CKI-7 free base is a potent and ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1), and MSK1.

The treatment of CKI-7 (0.1-10 μM; 5 days; ES cells) significantly increases the expression of the early neuroectodermal marker Sox1 and the number of cells positive for the neural markers βIII-tubulin and nestin, in a concentration-dependent manner. CKI-7 (5 μM; 5 days; ES cells) treatment suppresses SFEB-induced β-catenin stabilization on day 5 [1].

In vivo dose-dependent, the anti-tumor activity of CKI-7 is demonstrated in a SCID-Beige mouse systemic tumor model utilizing isolated Philadelphia chromosome-positive acute lymphoblastic leukemia cell line. Exposure to CKI-7 results in a cell cycle-dependent caspase 3 activation and apoptotic cell death [2].

120615-25-0

C11H12ClN3O2S

285.75

CKI-7

DMSO:25 mg/mL (87.49 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years